A synthetic chimeric peptide harboring human papillomavirus 16 cytotoxic T lymphocyte epitopes shows therapeutic potential in a murine model of cervical cancer

[1]  M. Wahiduzzaman,et al.  Human papillomavirus 16 L1-E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer. , 2012, Vaccine.

[2]  S. Piersma,et al.  Immunosuppressive Tumor Microenvironment in Cervical Cancer Patients , 2011, Cancer Microenvironment.

[3]  Kutlu G. Elpek,et al.  Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. , 2009, Cancer research.

[4]  S. H. van der Burg,et al.  Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity , 2008, Clinical Cancer Research.

[5]  S. H. van der Burg,et al.  Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine , 2008, Clinical Cancer Research.

[6]  A. Chopra,et al.  Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection. , 2007, Vaccine.

[7]  R. Roden,et al.  How will HPV vaccines affect cervical cancer? , 2006, Nature Reviews Cancer.

[8]  D. Hoskin,et al.  Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. , 2006, Vaccine.

[9]  S. H. van der Burg,et al.  Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. , 2005, Vaccine.

[10]  T. Wu,et al.  Cancer immunotherapy using a DNA vaccine encoding a single-chain trimer of MHC class I linked to an HPV-16 E6 immunodominant CTL epitope , 2005, Gene Therapy.

[11]  Chien-Fu Hung,et al.  Development of a DNA Vaccine Targeting Human Papillomavirus Type 16 Oncoprotein E6 , 2004, Journal of Virology.

[12]  Gajendra P.S. Raghava,et al.  Prediction of CTL epitopes using QM, SVM and ANN techniques. , 2004, Vaccine.

[13]  T. Wu,et al.  Comparison of HPV DNA vaccines employing intracellular targeting strategies , 2004, Gene Therapy.

[14]  Y. Tsao,et al.  Cytotoxic-T-Lymphocyte Human Papillomavirus Type 16 E5 Peptide with CpG-Oligodeoxynucleotide Can Eliminate Tumor Growth in C57BL/6 Mice , 2004, Journal of Virology.

[15]  M. Weinstein,et al.  A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV‐16/18 vaccine , 2003, International journal of cancer.

[16]  T. Rohan,et al.  Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. , 2003, Journal of the National Cancer Institute.

[17]  W. Ahn,et al.  Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. , 2002, Cancer research.

[18]  S. H. van der Burg,et al.  Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides1 , 2002, The Journal of Immunology.

[19]  R. Offringa,et al.  Differential binding of viral peptides to HLA‐A2 alleles. Implications for human papillomavirus type 16 E7 peptide‐based vaccination against cervical carcinoma , 1999, European journal of immunology.

[20]  S. Stacey,et al.  Priming in vivo and quantification in vitro of class I MHC-restricted cytotoxic T cells to human papilloma virus type 11 early proteins (E6 and E7) using immunostimulating complexes (ISCOMs). , 1996, Vaccine.

[21]  H. zur Hausen,et al.  Papillomavirus infections--a major cause of human cancers. , 1996, Biochimica et biophysica acta.

[22]  H. Grey,et al.  Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. , 1995, Journal of immunology.

[23]  V. Moreno,et al.  Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. , 1995, Journal of the National Cancer Institute.

[24]  G. Tortolero-Luna,et al.  Studies on in vivo induction of cytotoxic T lymphocyte responses by synthetic peptides from E6 and E7 oncoproteins of human papillomavirus type 16. , 1995, Viral immunology.

[25]  B. Chain,et al.  Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector. , 1994, Journal of General Virology.

[26]  M. Feltkamp,et al.  Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells , 1993, European journal of immunology.